Pagibaximab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 458268782

| image =

| type = mab

| mab_type = mab

| source = xi/o

| target = staphylococcal lipoteichoic acid

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|correct|CAS}}

| CAS_number = 595566-61-3

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 23KB56UHN9

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| C=6462 | H=9996 | N=1728 | O=2028 | S=54

| molecular_weight =

}}

Pagibaximab is a chimeric monoclonal antibody for the prevention of staphylococcal sepsis in infants with low birth weight. {{As of|2010|3}}, it is undergoing Phase II/III clinical trials.{{cite journal | vauthors = Weisman LE, Thackray HM, Garcia-Prats JA, Nesin M, Schneider JH, Fretz J, Kokai-Kun JF, Mond JJ, Kramer WG, Fischer GW | display-authors = 6 | title = Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates | journal = Antimicrobial Agents and Chemotherapy | volume = 53 | issue = 7 | pages = 2879–86 | date = July 2009 | pmid = 19380597 | pmc = 2704668 | doi = 10.1128/AAC.01565-08 }}{{ClinicalTrialsGov|NCT00646399|Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis}}